Longboard Pharmaceuticals... (LBPH)
59.98
null (null%)
At close: Nov 29, 2024, 6:00 PM
undefined% (1D)
| Bid | n/a |
| Market Cap | 2.34B |
| Revenue (ttm) | 8K |
| Net Income (ttm) | -76.34M |
| EPS (ttm) | -2.25 |
| PE Ratio (ttm) | -26.657777777777778 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | n/a |
| Volume | 0 |
| Avg. Volume (20D) | 0 |
| Open | undefined |
| Previous Close | undefined |
| Day's Range | 59.98 - 59.98 |
| 52-Week Range | 59.98 - 59.98 |
| Beta | 1.09 |
About LBPH
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurolog...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 12, 2021
Employees 50
Stock Exchange NASDAQ
Ticker Symbol LBPH
Website https://www.longboardpharma.com
Analyst Forecast
According to 8 analyst ratings, the average rating for LBPH stock is "Buy." The 12-month stock price forecast is $60, which is an increase of 0.03% from the latest price.
Stock Forecasts6 months ago
+51.65%
Longboard Pharmaceuticals shares are trading highe...
Unlock content with
Pro Subscription
7 months ago
+13.95%
Longboard Pharmaceuticals shares are trading higher after the company announced it received rare pediatric disease and orphan drug designations from the FDA for bexicaserin (LP352) in Dravet syndrome.
